Search

Population screening; Liver fibrosis; Early diagnosis Cribratge de població; Fibrosi hepàtica; Diagnòstic precoç Cribado de población; Fibrosis hepática; Diagnóstico precoz Cirrhosis, highly prevalent worldwide, develops after years of hepatic inflammation triggering progressive fibrosis. Currently, the main etiologies of cirrhosis are non-alcoholic fatty liver disease and alcohol-related liver disease, although chronic hepatitis B and C infections are still major etiological factors in some areas of the world. Recent studies have shown that liver fibrosis can be assessed with relatively high accuracy noninvasively by serological tests, transient elastography, and radiological methods. These modalities may be utilized for screening for liver fibrosis in at-risk populations. Thus far, a limited number of population-based studies using noninvasive tests in different areas of the world indicate that a significant percentage of subjects without known liver disease (around 5% in general populations and a higher rate −18% to 27%-in populations with risk factors for liver disease) have significant undetected liver fibrosis or established cirrhosis. Larger international studies are required to show the harms and benefits before concluding that screening for liver fibrosis should be applied to populations at risk for chronic liver diseases. Screening for liver fibrosis has the potential for changing the current approach from diagnosing chronic liver diseases late when patients have already developed complications of cirrhosis to diagnosing liver fibrosis in asymptomatic subjects providing the opportunity of preventing disease progression. LiverScreen Consortium and the European Commission under the H20/20 program (847989); AGAUR (2017SGR-01281); Centro de Investigacion Biomedica en Enfermedades Hepaticas y Digestivas; Fundación de Investigación Sanitaria, cofunded by Instituto Carlos III–Subdirección General de Evaluación and the European Regional Development Fund (PI18/01330, PI18/00662, and PI18/00862); and Gilead’s Investigator–sponsored research program (IN-ES-989-5309)

Chagas disease; Community pharmacies; Rapid test Enfermedad de Chagas; Farmacias comunitarias; Test rapido Malaltia de Chagas; Farmàcies comunitàries; Prova ràpida Objectives: This study aimed to report the protocol and results from the pilot phase of an opportunistic CP-based CD screening program in Barcelona, Spain. Methods: Three strategies according to recruitment approach were designed: passive, active and active-community. The study process consisted of signing the informed consent form, recording the patient’s data in a web-based database system, and performing the rapid test and blood collection on dry paper. Results: Nineteen pharmacies participated and 64 patients were included during the pilot phase of the study. The rapid diagnostic test (RDT) was positive in 2/64 (3.13%) cases. Of the 49 DBS samples that arrived at the laboratory, 22 (45%) were collected incorrectly. After quantitative and qualitative assessment of the program, the dry paper sample and passive strategy were ruled out. Conclusion: DBS sampling and the passive strategy are not suitable for CD screening in community pharmacies. There is a need to expand the number of participating pharmacies and individuals to determine whether conducting a RDT in community pharmacies is an effective screening method to increase access to CD diagnosis in a non-endemic area. This work has been supported by the Fundació la Marató TV3 (project number 481/U/2018).

Background and AimsImmunotherapy with immune checkpoint inhibitors (ICIs) is a pillar of many advanced tumors. However, there is scarce data concerning the rate of viral hepatitis screening in this population or the risk of viral reactivation.MethodsRetrospective–prospective study that includes all patients who began ICIs between January/2019 and December/2020 in a University Hospital. Data on viral hepatitis screening prior to the beginning of ICIs were collected. In subjects lacking information, serological tests were requested prospectively. Among HBsAg, anti-HBc, or anti-HCV positive subjects, reactivation was prospectively assessed.ResultsDuring the 2-year period of study, 595 subjects received ICIs (61.2% male, mean age 63 years). The most prevalent cancers found were 35.5% lung cancer, 12.1% melanoma, and 8.2% head and neck; ICIs schemes were mainly anti-PD1 (65.7%), followed by anti-PD-L1 (19.2%), and combined therapy (13.6%). Prior to immunotherapy, anti-HCV screening was performed in 462 (77.6%) subjects, HBsAg in 462 (77.6%), anti-HBc in 335 (56.3%), and the complete screening in 328 (55.1%). The anti-HBc screening was more frequently ordered among patients treated with concomitant systemic therapy (p = 0.003), especially in the case of chemotherapy (p = 0.015), though HCV screening was more commonly performed in concomitant therapies different from chemotherapy (p = 0.001). Serological tests were completed prospectively in those alive, leading to an overall prevalence for anti-HCV of 3.5%, HBsAg at 1.3%, and anti-HBc of 15.2%. HCV-RNA was detected in 2/19 (both patients with hepatocellular carcinoma), HBV-DNA in 4/7 HBsAg positive, and in 1/75 anti-HBc positive subject. Five out of the 7 HBsAg carriers and 1/75 anti-HBc+ subjects (due to concomitant antiretroviral therapy) received antiviral prophylaxis. Neither cases of HBV reactivation nor changes in HCV viral load were observed.DiscussionHBV and HCV screening prior to immunotherapy is suboptimal. Though the rate of viral hepatitis reactivation seems extremely low, efforts should be made to optimize viral hepatitis screening prior to immunotherapy for the selection of candidates for either antiviral prophylaxis or periodical follow-up.

NCL2 disease; Dried blood spot; Enzymatic activity Enfermedad de NCL2; Mancha de sangre seca; Actividad enzimática Malaltia de NCL2; Taca de sang seca; Activitat enzimàtica Introduction: Neuronal Ceroid Lipofuscinosis (NCL) comprises a clinically and genetically heterogeneous group of 13 neurodegenerative lysosomal storage disorders. Neuronal Ceroid lipofuscinosis type 2 disease (NCL2), caused by the deficient lysosomal enzyme tripeptidyl peptidase 1 (TPP1), is the only one with an approved enzyme replacement treatment (ERT). Early initiation of ERT appears to modify significantly the natural history of the disease. We aimed to shorten the time to diagnosis of NCL2. Methods: In March 2017, we started per first time in Spain a selective screening program, the LINCE project, in pediatric patients with clinical symptoms compatible with NCL2 disease. The program covered the whole country. We distributed kits to pediatricians with the necessary material to assess patients. All samples in this study were received within one week of collection. Enzymatic activity determined on dried blood spots was the main method used to screen for TPP1 and palmitoyl protein thioesterase 1 (PPT1) for the differential diagnosis with neuronal ceroid lipofuscinosis type 1 (NCL1). Results: Over a period of three years, we received 71 samples. The analysis was minimally invasive, relatively cheap and fast-executing. Three cases identified as a direct result of the selective screening strategy were confirmed by genetic study of NCL2 disease with a median age of 4.5 years. Our screening method has a specificity of 100%, and, with the absence to date of false negatives. We did not detect any NCL1-positive cases. Conclusions: LINCE proved to be a simple, useful, and reliable tool for the diagnosis of NCL2, enabling clinicians to diagnose NCL2 faster. The presence of NCL2-positive cases in our population and availability of treatment may facilitate the inclusion of NCL2 in neonatal screening programs for early diagnosis. This study received funding from Grant Biomarin Inc. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.

In this study, we examined normative data and diagnostic accuracy of a pictorial screening test to detect memory impairment for mild cognitive impairment (MCI) and Alzheimer’s disease (AD) in Spanish-speaking adults with intellectual disability (ID). A total of 94 volunteers with ID (60 controls, 17 MCI, and 17 AD), were evaluated by neuropsychological tests including the PMIS-ID in a cross-sectional validation study. Discriminative validity between the MCI, AD, and control group was analyzed by the area under the ROC curve. A cut-off score of 4.5 on the immediate recall trial had a sensitivity of 69% and a specificity of 80% to detect memory impairment (AUC = 0.685; 95% CI = 0.506–0.863) in the AD group. The PMIS-ID is a useful screening test to rule out a diagnosis of memory decline in people with moderate level of ID and AD, and it shows good psychometric properties.

Background We aimed to identify the risk factors associated with early, late and long-term readmissions in women diagnosed with breast cancer participating in screening programs. Methods We performed a multicenter cohort study of 1055 women aged 50–69 years participating in Spanish screening programs, diagnosed with breast cancer between 2000 and 2009, and followed up to 2014. Readmission was defined as a hospital admission related to the disease and/or treatment complications, and was classified as early ( 1 year). We used logistic regression to estimate the adjusted odds ratios (aOR), and 95% confidence intervals (95% CI) to explore the factors associated with early, late and long-term readmissions, adjusting by women’s and tumor characteristics, detection mode, treatments received, and surgical and medical complications. Results Among the women included, early readmission occurred in 76 (7.2%), late readmission in 87 (8.2%), long-term readmission in 71 (6.7%), and no readmission in 821 (77.8%). Surgical complications were associated with an increased risk of early readmissions (aOR = 3.62; 95%CI: 1.27–10.29), and medical complications with late readmissions (aOR = 8.72; 95%CI: 2.83–26.86) and long-term readmissions (aOR = 4.79; 95%CI: 1.41–16.31). Conclusion Our results suggest that the presence of surgical or medical complications increases readmission risk, taking into account the detection mode and treatments received. Identifying early complications related to an increased risk of readmission could be useful to adapt the management of patients and reduce further readmissions. Trial Registration ClinicalTrials.govIdentifier: NCT03165006. Registration date: May 22, 2017 (Retrospectively registered).

OBJECTIVE: To analyse mammography screening in Spanish women aged 45 to 69 according sociodemographic variables and to describe the role of population-based breast cancer screening programmes in terms of variability of said screening. METHODS: Cross-sectional study of the 2011 National Health Survey. The study population includes women living in Spain between late 2011 and early 2012. The weighted sample analysed corresponds to 3,086 women aged 45 to 69. The dependent variables were mammograms and when the last mammogram was performed and why. Independent variables were age, social class, occupational status, country of origin, area of origin (rural/urban), health cover and years the programme had been in place. Logistic regression models were performed, with odds ratio (OR) adjusted according to age and 95% confidence intervals (95% CI). RESULTS: Approximately 91.9% indicated that they had had a mammogram before. The women who had had their last mammography screening in the previous 1 to 2 years were associated with the highest social class (OR: 1.69; 95% CI: 1.03-2.75). The reason for performing the last periodic mammogram via a population-based programme was associated with women aged between 60 and 69 years (OR: 1.51; 95% CI: 1.04-2.19). CONCLUSIONS: The results show that there are still inequalities in preventive practices. Possible risk groups need to be identified in order to promote the implementation of specific actions. Objetivo: Analizar según variables sociodemográficas el control mamográfico que realizan las mujeres españolas de 45 a 69 años de edad y describir el papel que desempeñan los programas poblacionales de cribado del cáncer de mama en cuanto a la variabilidad de los controles mamográficos. Métodos: Estudio transversal a partir de la Encuesta Nacional de Salud de 2011. La población de estudio son las mujeres residentes en España entre finales de 2011 y principios de 2012. La muestra ponderada analizada corresponde a 3.086 mujeres de 45 a 69 años de edad. Las variables dependientes fueron la realización de mamografías, la última mamografía y el motivo de su realización. Las variables independientes fueron la edad, la clase social, la situación laboral, el país de origen, el ámbito de procedencia, la cobertura sanitaria y los años de implantación del programa. Se realizaron modelos de regresión logística, obteniendo odds ratio (OR) ajustadas por edad y sus intervalos de confianza del 95% (IC95%). Resultados: Un 91,9% indicó que se había realizado una mamografía alguna vez. Las mujeres que se habían realizado el último control mamográfico entre 1 y 2 años antes se asociaron a la clase social más alta (OR: 1,69;IC95%: 1,03-2,75). El motivo de realizar la última mamografía periódica por un programa poblacional se asoció a las mujeres cuya edad era de 60-69 años (OR: 1,51; IC95%: 1,04-2,19). Conclusión: Los resultados indican que existen desigualdades sociales en la realización de prácticas preventivas. Debemos identificar posibles grupos de riesgo con el fin de impulsar la implementación de acciones específicas.

El uso de los instrumentos de cribado en salud mental infantil en el ámbito pediátrico y escolar es heterogéneo e insuficiente. Partiendo de esta premisa surge la necesidad de hacer una revisión de la literatura sobre los instrumentos de cribado y el uso que se otorga en salud mental infantil (0-6 años) en la consulta pediátrica y el contexto escolar. Se ha llevado a cabo una búsqueda de la literatura publicada en el período de 2005-2015 en las bases de datos Discovery, Eric y Medline. Existe una gran diferencia de uso de los instrumentos de cribado entre el ámbito escolar y la consulta pediátrica. En la escuela la administración de instrumentos es más habitual y con menores limitaciones. En la consulta pediátrica, aunque existen numerosos instrumentos validados psicométricamente, no se aplican con tanta frecuencia. La mayor limitación en los dos ámbitos es la falta de seguimiento después de la derivación del niño a los servicios de salud mental. La escuela y la consulta pediátrica son contextos con características idóneas para la prevención en salud mental infantil. Es necesario seguir investigando para mejorar la detección, derivación y seguimiento a los servicios de salud mental. The use of child mental health screening tools in the paediatric and school fields is heterogeneous and insufficient. From this assumption, we can see the need to conduct a literature review on screening tools and their use for child mental health (0-6-year-olds) in the paediatric ward and the school context. A search was carried out throughout literature published in the period 2005-2015 in the databases Discovery, Eric, and Medline. There is a remarkable different use of screening tools between the school context and the paediatric ward. At school, the administration of instruments is more usual and with fewer limitations. At the paediatric ward, although there are many psychometrically validated instruments, they are not used so frequently. The main limitation in both settings is the lack of follow-up after the child’s referral to mental health services. The school and the paediatric ward are contexts with ideal characteristics for prevention in child mental health. Further research is needed to improve the detection, referral to, and follow-up in mental health services.

Resting 12-lead electrocardiogram (ECG) has been employed in the evaluation of young asymptomatic subjects to detect pre-existing heart diseases. Although the incorporation of routine ECG remains controversial, there is increasing evidence that cardiomyopathies and ion channelopathies show ECG changes as the initial manifestation. The causes of sudden cardiac death in young people show a significant geographical variation. We aim to determine the prevalence and spectrum of ECG findings in a youth population. Methodology: From May 2010 to April 2013, a total of 976 young secondary school students (mean age, 14 years; range, 13-15) underwent voluntary medical screening that included a resting 12-lead ECG and structured clinical survey. Subjects with abnormal ECG findings were classified into two groups: major ECG findings group, which fulfilled a pre-specified checklist to screen for principal structural and electrical cardiopathies, and minor ECG findings group showing other ECG changes. The major ECG findings group was referred for secondary diagnostic tests at a tertiary institution. Results: Of the 976 subjects screened, 252 (25.82%; CI95%, 23.17-28.66) had ECG findings. Of note, 17 (1.74%) had major findings and 235 (24.08%) had minor findings on ECG. The prevalence of cardiovascular pathology within the major ECG findings group was 35.29%. The prevalence of ECG abnormalities was significantly higher in males than in females (29% vs 20.9%, P

Grupo de estudio RAFP: IMIM-Hospital del Mar, Parc de Salut Mar, Barcelona: Xavier Castells, Francesc Macià, Marta Román, María Sala. Servicio de programas poblacionales de cribado, Xunta de Galicia: Raquel Almazán, Ana Belén Fernández, María Teresa Queiro, Raquel Zubizarreta. Programa de Detección Precoz de Cáncer de Mama de Navarra, Instituto de Salud Pública, Pamplona: Nieves Ascunce, María Ederra, Nieves Erdozain, Iosu Delfrade. Dirección General de Salud Pública y Centro Superior de Investigación en Salud Pública (CSISP), Generalitat Valenciana: Dolores Cuevas, Josefa Ibáñez, Josefa Miranda, Dolores Salas. Servicio Canario de la Salud, Islas Canarias: María Obdulia de la Vega, Isabel Díez de la Lastra. Fundació Lliga per a la Recerca i Prevenció del Càncer, Institut d’Investigació Sanitària Pere Virgili, Reus, Tarragona: Jaume Galceran. Unidad de Análisis y Programas, Departamento de Salud, Asturias: Carmen Natal. Programa de Detección Precoz de Cáncer de Mama, La Rioja. Fundación Rioja Salud, Logroño: Araceli Baroja. Sección de Promoción y Protección de la Salud. Corporació Parc Taulí-Institut Universitari Parc Taulí (UAB), Sabadell: Marisa Baré. Castilla-León Programa de Detección Precoz de Cáncer de Mama. Dirección General de Salud Pública ID e I. SACYL. Castilla y León: Isabel González-Román Grupo de estudio RAFP Digital: IMIM-Hospital del Mar, Parc de Salut Mar, Barcelona: Francesc Belvis, Xavier Castells, María Sala. Hospital Santa Caterina, Girona: Joana Ferrer. Dirección General de Salud Pública y Centro Superior de Investigación en Salud Pública (CSISP), Generalitat Valenciana: Josefa Ibáñez, María Soledad Laso, Dolores Salas. Cantabria: Mar Sánchez, Alfonso Vega Grupo de estudio INCA: IMIM-Hospital del Mar, Parc de Salut Mar, Barcelona: Jordi Blanch, Xavier Castells, Mercè Comas, Laia Domingo, Francesc Macià, Juan Martínez, Marta Román, Anabel Romero, María Sala. Dirección General de Salud Pública y Centro Superior de Investigación en Salud Pública (CSISP), Generalitat Valenciana: Carmen Alberich, Josefa Ibáñez, Amparo Lluch, Josefa Miranda, Dolores Salas, Ana Torrella. Servicio de Programas Poblacionales de Cribado, Xunta de Galicia: Raquel Almazán, Miguel Conde, Montserrat Corujo, Ana Belén Fernández, Raquel Zubizarreta. Servicio de Programas Oncológicos, Servicio Canario de la Salud: Teresa Barata, Isabel Díez de la Lastra, Juana María Reyes. Programa de Detección Precoz del Cáncer de Mama-Osakidetza, País Vasco: Arantza Otegi, Garbiñe Sarriugarte. Hospital Parc Taulí, Sabadell: Marisa Baré, Núria Torà. Hospital Santa Caterina, Girona: Joana Ferrer, Gemma Renart. Registro de Cáncer de Girona, Institut Català d’Oncologia: Rafael Marcos-Gragera, Montserrat Puig. Universitat de Lleida: Carles Forné, Montse Martínez-Alonso, Albert Roso, Montse Rué, Ester Vilaprinyó. Universitat Rovira i Virgili, Tarragona: Misericordia Carles, Aleix Gregori, María José Pérez. Regió Sanitària Terres de l’Ebre: Roger Pla The consolidation of breast cancer screening programs, with full coverage of the target population in all Spanish regions, has encouraged the beginning of a joint research strategy. This strategy aims to improve the effectiveness of breast cancer screening by gathering information from distinct screening programs. Methods A retrospective cohort with information on over 1.5 million screened women was constructed to evaluate risk factors for a false-positive result. The impact of the change from digital mammography to screen-film mammography was evaluated, while results for interval cancers and false negatives are currently being studied. Results The results are highly useful from the perspective of public health, as they can be used to identify and improve the information provided to women with a higher risk of experiencing an adverse effect. These results will also be helpful to identify screening program-related characteristics and women's personal characteristics, which will allow better prevention strategies to be developed. Conclusions The results obtained will be included in mathematical models currently under development to evaluate the efficiency of breast cancer screening. These models could be highly useful to provide information and guide clinical and health policy decisions on cancer prevention and control La finalización del despliegue de los programas de detección precoz de cáncer de mama en todas las comunidades autónomas de España ha facilitado el inicio de una investigación conjunta, con información procedente de varios programas, orientada a mejorar su efectividad. Métodos Se ha construido una cohorte de más de 1 millón de mujeres cribadas para evaluar el riesgo y los determinantes de los resultados falsos positivos. Se ha evaluado el impacto del cambio de técnica de mamografía analógica a digital y se está estudiando el cáncer de intervalo y los resultados falsos negativos. Resultados Los resultados ofrecen información muy útil, desde el punto de vista de salud pública, para identificar e informar mejor a las mujeres con mayor riesgo de presentar efectos adversos, a la vez que ayudará a identificar características ligadas a los programas y a las mujeres que permitan establecer mejores estrategias de prevención. Conclusiones Estos resultados se incorporarán a los modelos matemáticos sobre evaluación de la eficiencia de los programas que se están desarrollando actualmente. Modelos que pueden ser de gran utilidad como herramienta dirigida a informar y guiar las decisiones clínicas y de planificación sanitaria sobre el control del cáncer

Hipoacúsia; Cribratge; Potencials evocats automatitzats; Registre Hipoacusia; Cribado; Potenciales evocados automatizados; Registro Hearing loss; Screening; Automated evoked potentials; Registry Introducció: Des de l’any 2010 s’ha desplegat a la xarxa sanitària pública de Catalunya un programa de cribratge de la hipoacúsia. Durant l’any 2015 s’ha aprovat el Decret 4/2015, de 13 de gener, per estendre la cobertura del Programa de manera universal. Per aplicar-lo s’han realitzat diferents sessions de coordinació i s’ha ofert formació al cent per cent dels centres sanitaris privats. Objectiu: L’objectiu del treball és avaluar el Programa de detecció precoç de la hipoacúsia mitjançant els indicadors de procés i resultats i descriure les novetats amb la incorporació recent en el Programa de cribratge dels centres sanitaris privats (Decret 4/2015, de 13 de gener). Mètodes: Estudi descriptiu dels indicadors de procés i resultats del Registre del Programa de detecció precoç de la hipoacúsia a Catalunya des de l’inici, l’any 2010, fins al 2015. Descripció del procés d’extensió del Programa a la xarxa de centres privats. Resultats: El nombre de nadons als quals s’ha fet el cribratge ha passat de 9.178 el 2010 a 44.632 el 2015, fet que representa un increment del 386%. Això significa una cobertura el 2015 del 91,7% dels nadons nascuts en centres de la xarxa pública. Es van diagnosticar un total de 468 casos (xifra acumulada del període 2010-2015), dels quals 110 van ser registrats l’any 2014. El 2015 es van detectar 80 nadons amb hipoacúsia (dades provisionals). Conclusions: El Programa presenta una bona cobertura a la xarxa sanitària pública i a la xarxa sanitària privada s’està impulsant com a programa de salut pública de cobertura universal. Aquesta iniciativa promou que els centres i serveis maternals privats que el 2015 s’han incorporat al Programa declarin al Registre els casos de nadons diagnosticats d’hipoacúsia, així com que els centres i serveis maternals públics continuïn mantenint les bones cobertures i la declaració Introducción: Desde el año 2010 se ha desplegado en la red sanitaria pública de Cataluña un programa de cribado de la hipoacusia. Durante el año 2015 ha sido aprobado el Decreto 4/2015, de 13 de enero, para extender la cobertura del Programa de forma universal. Para aplicarlo se han realizado diferentes sesiones de coordinación y se ha ofrecido formación al cien por cien de los centros sanitarios privados. Objetivo: El objetivo del trabajo es evaluar el Programa de detección precoz de la hipoacusia mediante los indicadores de proceso y resultados y describir las novedades con la reciente incorporación en el Programa de cribado de los centros sanitarios privados (Decreto 4/2015, de 13 de enero). Métodos: Estudio descriptivo de los indicadores de proceso y resultados del Registro del Programa de detección precoz de la hipoacusia en Cataluña desde su inicio, el año 2010, hasta el 2015. Descripción del proceso de extensión del Programa en la red de centros privada. Resultados: El número de recién nacidos a los que se ha hecho el cribado ha pasado de 9.178 el 2010 a 44.632 el 2015, lo que representa un incremento del 386%. Esto significa una cobertura el 2015 del 91,7% de los niños nacidos en la red pública. Se diagnosticaron un total de 468 casos (cifra acumulada del período 2010-2015), de los cuales 110 se registraron en el año 2014. En el 2015 se detectaron 80 recién nacidos con hipoacusia (datos provisionales). Conclusiones: El Programa presenta una buena cobertura en la red sanitaria pública y en la red sanitaria privada se está impulsando como programa de salud pública de cobertura universal. Esta iniciativa promueve que los centros y servicios maternales privados que en el 2015 se han incorporado al Programa declaren en el Registro los casos de recién nacidos diagnosticados de hipoacusia, así como que los centros y servicios maternales públicos sigan manteniendo las buenas coberturas y la declaración en el Registro. Existe una buena interrelación entre los diferentes agentes implicados en el cribado. Introduction: A screening programme for hearing loss is being implemented within the Catalan Public Hospital Network since 2010. In 2015 Decree 4/2015, of 13 January, was approved to extend a universal screening coverage. To implement it, different sessions were conducted for coordination and training was offered to a hundred percent of private healthcare centers. Objective: The objective is to assess the Early Hearing Loss Detection Programme through the process indicators and results describing the innovation with the recent addition of private centers (Decree 4/2015, of 13 January). Methods: Descriptive study of process indicators and results of the Early Hearing Loss Detection Programme in Catalonia record since the beginning – in 2010 – to 2015. Description of the extension process in the private centers network. Results: The number of screened newborns has passed from 9,178 (2010) to 44,632 (2015), which represents a 386% increase. In 2015, this represents a coverage of 91,7%. 468 cases were diagnosed (from 2010 to 2015) and 110 were diagnosed in 2014. In 2015 80 newborns were diagnosed with hearing loss (provisional data). Conclusions: The Programme presents good coverage in the Catalan Public Hospital Network, whilst in the private health network it is being fostered as a universal coverage public health programme. This initiative promotes that all the cases of newborns diagnosed with hearing loss are reported by private birth centers to the record, while public birth centers keep mantaining good coverage and reporting. There is good interaction among the different agents involved in the screening.

Cribratge neonatal; Detecció de malalties; Metabolopaties congènites; Neonatal screening; Disease detection; Inborn errors of metabolism; Cribado neonatal; Detección de enfermedades; Metabolopatías congénitas Aquest informe pretén revisar la situació actual del cribratge neonatal a Catalunya, juntament amb la resta de les comunitats autònomes, Europa i els Estats Units, i un cop revisada l’evidència científica existent, presentar propostes de futur amb vista a l’ampliació progressiva del Programa de cribratge neonatal a Catalunya.

Osteoporosi; Cribatge; Atenció primària Osteoporosis; Cribado; Atención primaria Osteoporosis; Screening; Primary care Síntesi dels principals resultats d'un informe elaborat per l'EUnetHTA OTCA19 Assessment Team a partir de la revisió bibliogràfica del cribratge de l'osteoporosi en la població general a l'atenció primària.

Cribratge neonatal; Detecció de malalties; Metabolopaties congènites; Neonatal screening; Disease detection; Inborn errors of metabolism; Cribado neonatal; Detección de enfermedades; Metabolopatías congénitas Aquest informe pretén revisar la situació actual del cribratge neonatal a Catalunya, juntament amb la resta de les comunitats autònomes, Europa i els Estats Units, i un cop revisada l’evidència científica existent, presentar propostes de futur amb vista a l’ampliació progressiva del Programa de cribratge neonatal a Catalunya.

Screening; Addicts; Urinalysis Cribratge; Addictes; Uroanàlisi Cribado; Adictos; Uroanálisis Esencial es una iniciativa que identifica prácticas clínicas de poco valor y promueve recomendaciones para evitar su realización. En este caso, se trata el cribado indiscriminado de sustancias de abuso que supone un gasto elevado e injustificado. El análisis de las muestras según un plan personalizado basado en la evolución del paciente, o el análisis de muestras seleccionadas de forma aleatoria serían las opciones más recomendadas. Essencial és una iniciativa que identifica pràctiques clíniques de poc valor i promou recomanacions per tal d'evitar-ne la realització. En aquest cas, es tracta el cribratge indiscriminat de substàncies d'abús que suposa una despesa elevada i injustificada. L'anàlisi de les mostres segons un pla personalitzat basat en l’evolució del pacient, o l'anàlisi de mostres seleccionades de forma aleatòria serien les opcions més recomanades

Malaltia renal crònica; Cribratge; Prevalença; Estadiatge Enfermedad renal crónica; Cribado; Prevalencia; Estadiaje Chronic kidney disease; Screening; Prevalence; Staging Informe que analitza el cribratge que es fa a l'atenció primària de l'ICS per al diagnòstic de la malaltia renal crònica, com se'n fa el diagnòstic i quina n'és la prevalença. També mostra quin és l'estadiatge de la malaltia.

Onada migratòria; Cribatge clínic; Vacunacions Ola migratoria; Cribado clínico; Vacunaciones Migratory wave; Clinical screening; Vaccinations Els objectius d’aquest protocol que es va impulsar inicialment amb l’onada migratòria de l’estiu 2018 són: Promoure i millorar la salut dels refugiats migrants, i d’aquells que, tot i no ser refugiats, són migrants amb especial incidència en els grups en situació de vulnerabilitat. / Prevenir malalties i detectar ràpidament qualsevol problema de salut. / Oferir en un marc general recomanacions sobre les actuacions immediates de cribratge i vacunacions que hauran d’operativitzar-se en els diferents punts del territori.

Screening; Addicts; Urinalysis Cribratge; Addictes; Uroanàlisi Cribado; Adictos; Uroanálisis Esencial es una iniciativa que identifica prácticas clínicas de poco valor y promueve recomendaciones para evitar su realización. En este caso, se trata el cribado indiscriminado de sustancias de abuso que supone un gasto elevado e injustificado. El análisis de las muestras según un plan personalizado basado en la evolución del paciente, o el análisis de muestras seleccionadas de forma aleatoria serían las opciones más recomendadas. Essencial és una iniciativa que identifica pràctiques clíniques de poc valor i promou recomanacions per tal d'evitar-ne la realització. En aquest cas, es tracta el cribratge indiscriminat de substàncies d'abús que suposa una despesa elevada i injustificada. L'anàlisi de les mostres segons un pla personalitzat basat en l’evolució del pacient, o l'anàlisi de mostres seleccionades de forma aleatòria serien les opcions més recomanades

Càncer colorectal; Cribratge; Factors socioeconòmics Neoplasias colorrectales; Cribado; Factores socioeconómicos Colorectal Neoplasms; Screening; Socioeconomic Factors BACKGROUND Screening with faecal occult blood tests reduces colorectal cancer-related mortality; however, age, sex and socioeconomic factors affect screening outcomes and could lead to unequal mortality benefits. The aim of this study was to describe the main outcomes of the population-based Barcelona colorectal cancer screening programme (BCRCSP) by deprivation. METHODS: Retrospective study of the eligible population of the first round of the BCRCSP. Participants' postal addresses were linked with the MEDEA database to obtain the deprivation quintiles (Dq). Chi-squared tests were used to compare proportions across variables and logistic regression was used to estimate the adjusted effects of age, sex and deprivation on uptake, FIT positivity, colonoscopy adherence and advanced neoplasia detection rate. RESULTS: Overall uptake was 44.7%, higher in Dq2, 3 and 4 (OR 1.251, 1.250 and 1.276, respectively) than in the least deprived quintile (Dq 1), and lowest in Dq5 (OR 0.84). Faecal immunochemical test (FIT) positivity and the percentage of people with detectable faecal haemoglobin below the positivity threshold increased with deprivation. The advanced neoplasia detection rate was highest in Dq4. CONCLUSION: Unlike most regions where inequalities are graded along the socioeconomic continuum, inequalities in the uptake of colorectal cancer screening in Spain seem to be concentrated first in the most disadvantaged group and second in the least deprived group. The correlation of deprivation with FIT-positivity and faecal haemoglobin below the positivity threshold is worrying due to its association with colorectal cancer and overall mortality.